We only have limited information for this firm. Consider the following firms which have provided more information:

The practice at Basham, Ringe y Correa, S.C. draws on the firm’s full service capabilities to field a team that is at its strongest regarding the IP-side of the life sciences practice, particularly as regards patent-related matters, on behalf of a client list with a strong big pharma component. It also acts for a range of firms in the alimentary and tobacco sectors on regulatory matters and has niche engagement with medical software developers (currently an unregulated area in México). The practice is perhaps best known for its success in arguing for the extension of the length of patent terms due to time-losses as a result of patent office delays in the granting of patent protection, a case with particular relevance in the life sciences segment. It has also been active in relation to medical technology and devices, orphan drug designations and in the alcoholic beverages sector, recently. The practice group is co-led by Adolfo Athié, who focuses on intellectual property consulting and administrative litigation (and is also involved in IT and privacy and data protection matters); and Claudio Ulloa is principally active on patent related matters. On the corporate side, Juan Carlos Serra and Jesus Colunga provide transactional experience and the group can also call on the firm’s solid standing in international trade matters where necessary. A former Secretaria de Estudio y Cuenta at the Supreme Court, Diana Rangel arrived as a counsel at the firm in January 2023 and should add further to the team’s administrative litigation capabilities. However, key associate Carolina Nogal is currently undertaking her LLM.

Legal 500 Editorial commentary

Key clients

  • Bayer
  • Alexion Pharmaceuticals
Abbreviated data is displayed for this firm.

Work highlights

  • Assisted Jumex with advice on the status of diverse Mexican official Standards related to alcoholic beverages.
  • Prepared a legal opinion regarding Orphan Drug Designations (“ODD”) related to an of assignment of rights, and covering regulatory and contractual topics on behalf of Alexion.
Abbreviated data is displayed for this firm.